troglitazone has been researched along with Hyperandrogenism in 2 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Hyperandrogenism: A condition caused by the excessive secretion of ANDROGENS from the ADRENAL CORTEX; the OVARIES; or the TESTES. The clinical significance in males is negligible. In women, the common manifestations are HIRSUTISM and VIRILISM as seen in patients with POLYCYSTIC OVARY SYNDROME and ADRENOCORTICAL HYPERFUNCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Because troglitazone (Tgz) improves both hormonal profiles and insulin sensitivity, we tested whether Tgz treatment ameliorates endothelial function in these patients." | 9.10 | Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. ( Baron, AD; Hook, G; Paradisi, G; Shepard, MK; Steinberg, HO, 2003) |
| "To determine whether amelioration of insulin resistance in polycystic ovary syndrome (PCOS) with the insulin sensitizer troglitazone (TGZ) decreases circulating adrenal androgens (AAs), as reflected by DHEAS levels." | 9.10 | Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. ( Azziz, R; Ehrmann, DA; Fereshetian, AG; Ghazzi, MN; Legro, RS; O'Keefe, M, 2003) |
| " Because troglitazone (Tgz) improves both hormonal profiles and insulin sensitivity, we tested whether Tgz treatment ameliorates endothelial function in these patients." | 5.10 | Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. ( Baron, AD; Hook, G; Paradisi, G; Shepard, MK; Steinberg, HO, 2003) |
| "To determine whether amelioration of insulin resistance in polycystic ovary syndrome (PCOS) with the insulin sensitizer troglitazone (TGZ) decreases circulating adrenal androgens (AAs), as reflected by DHEAS levels." | 5.10 | Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. ( Azziz, R; Ehrmann, DA; Fereshetian, AG; Ghazzi, MN; Legro, RS; O'Keefe, M, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Paradisi, G | 1 |
| Steinberg, HO | 1 |
| Shepard, MK | 1 |
| Hook, G | 1 |
| Baron, AD | 1 |
| Azziz, R | 1 |
| Ehrmann, DA | 1 |
| Legro, RS | 1 |
| Fereshetian, AG | 1 |
| O'Keefe, M | 1 |
| Ghazzi, MN | 1 |
2 trials available for troglitazone and Hyperandrogenism
| Article | Year |
|---|---|
Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome.
Topics: Blood Glucose; Blood Pressure; Chromans; Endothelium, Vascular; Female; Humans; Hyperandrogenism; Hy | 2003 |
Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome.
Topics: Adrenal Glands; Adult; Blood Glucose; Chromans; Dehydroepiandrosterone Sulfate; Dose-Response Relati | 2003 |